论文部分内容阅读
目的:研究西黄胶囊联合GP方案对中晚期乳腺癌患者血清肿瘤坏死因子-α(TNF-α)、人血管内皮细胞生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)、基质金属蛋白酶-9(MMP-9)的影响。方法:入选2014年3月至2015年2月我院收治的88例中晚期乳腺癌患者,按照患者入院顺序分为观察组和对照组,44例每组。对照组使用GP方案进行治疗,观察采取西黄胶囊联合GP方案进行治疗。比较两组患者治疗前后血清TNF-α、VEGF、MMP-2、MMP-9水平的变化、临床疗效和不良反应的发生情况。结果:观察组的总有效率显著高于对照组[84.09%(37/44)vs 50.00%(22/44)](P<0.05)。治疗前,两组患者血清TNF-α、VEGF、MMP-2、MMP-9水平比较差异无统计学意义(P>0.05);治疗后,两组患者的血清TNF-α、VEGF、MMP-2、MMP-9水平均较治疗前显著降低(P<0.05),观察组的血清TNF-α、VEGF、MMP-2、MMP-9水平均明显低于对照组(P<0.05)。两组患者恶心呕吐等不良反应率比较差异无统计学意义(P>0.05),观察组脱发、腹泻、肝功能异常、食欲下降、贫血、白细胞下降发生率明显低于对照组(P<0.05)。结论:西黄胶囊联合GP方案较单用GP方案能更有效降低中晚期乳腺癌患者血清TNF-α、VEGF、MMP-2、MMP-9水平,临床疗效更好,安全性更高。
OBJECTIVE: To study the effects of xihuang capsule combined with GP regimen on serum levels of tumor necrosis factor-α (TNF-α), human vascular endothelial cell growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) Protease-9 (MMP-9). Methods: A total of 88 patients with advanced breast cancer who were admitted to our hospital from March 2014 to February 2015 were divided into observation group and control group according to the sequence of admission, and 44 patients in each group. The control group was treated with GP regimen. The treatment of Xibei capsule combined with GP regimen was observed. The changes of serum TNF-α, VEGF, MMP-2 and MMP-9 levels, clinical efficacy and adverse reactions before and after treatment were compared between the two groups. Results: The total effective rate in the observation group was significantly higher than that in the control group [84.09% (37/44) vs 50.00% (22/44)] (P <0.05). Before treatment, the levels of serum TNF-α, VEGF, MMP-2 and MMP-9 in two groups had no significant difference (P> 0.05). After treatment, the levels of serum TNF-α, VEGF and MMP- (P <0.05). The levels of serum TNF-α, VEGF, MMP-2 and MMP-9 in the observation group were significantly lower than those in the control group (P <0.05). There was no significant difference in the rate of adverse reactions between the two groups (P> 0.05). The incidence of hair loss, diarrhea, abnormal liver function, decreased appetite, anemia and leukopenia in the observation group were significantly lower than those in the control group (P <0.05) . Conclusion: XHZ capsule combined with GP regimen is more effective than single GP regimen in reducing the serum levels of TNF-α, VEGF, MMP-2 and MMP-9 in patients with advanced breast cancer. The clinical effect is better and the safety is higher.